The Alzamend Story
“I vividly remember visiting my grandmother one day and not only did she not recognize me, but she feared me as though I were a stranger. Over the years as more than six other family members became affected by the disease, I studied and learned more about its devastating nature. I felt compelled to take action.”
– Chairman Milton “Todd” Ault III
Through his personal experience and diligent study of the status of treatments, and the landscape of medical technology, Mr. Ault, chose the Byrd Institute and their intellectual property, and formed Alzamend as his starting point to make a difference. Twenty-Five years of experience on Wall Street at buying and selling companies as an activist, and his relentless passion for business and technology has culminated in a commitment to depart from the traditional while forging ahead with a disruptive path to financing the commercialization and the discovery of future solutions.
Mr. Ault was quick to recognize the opportunity to make a difference in routine medical procedures that at times resulted in fatal consequences. He founded and launched Patient Safety Technologies Inc., believing in the impact of bar-coded sponge technology, long before anyone else would support it, and it is has now become the standard of care in operating rooms around the world, saving countless lives and subsequent lawsuits annually.
Providing a team of Operational and Financial executives with proven track records, Mr. Ault has made an all-star cast to move this vision forward, without burdening the company with excessive overhead.
Alzamend Neuro is a development stage biotechnology company which has licensed a patented mutant peptide developed by Dr. Chuanhai Cao at the college of Pharmacy of the University of South Florida (USF) and USF- Health Byrd Alzheimer’s Institute to develop a cell based therapeutic vaccine as an immunotherapy to prevent or slowdown Alzheimer’s disease. The therapy not only targets the pathological molecule that is associated to AD, it also is able to fix the impaired immune system associated to AD development.
The USF Health Byrd Alzheimer’s Institute “Byrd” is dedicated to the prevention, diagnosis, treatment and care of Alzheimer’s disease and related disorders.
With a state-of-the-art building and a highly qualified team of physicians, memory care specialists, researchers and educators, the Byrd is in the forefront of Alzheimer’s research and patient care. The rapid growth of the Institute and the need for groundbreaking approaches to the care and treatment of patients with memory disorders has led us to develop the concept of the Center for Memory C.A.R.E. (Clinical Assessment, Research & Education). The entire second floor of the Institute is a revolutionary Center that provides the most up-to-date diagnostic and caregiving services to patients and their families in One Place.